Preventing type 1 diabetes mellitus: the promise of gene therapy

Shimon Efrat1

  • 1Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. sefrat@post.tau.ac.il

American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|June 27, 2002
PubMed

Insights

Preventing type 1 diabetes involves early diagnosis through genetic and serological screening. Future strategies may include antigen-specific tolerance induction and gene therapy to enhance beta-cell resistance to autoimmunity.

Area of Science:

  • Immunology
  • Endocrinology
  • Genetics

Background:

  • Type 1 diabetes mellitus is an autoimmune disease without a cure, necessitating advanced treatment and prevention strategies.
  • Current treatments focus on insulin replacement and beta-cell transplantation, aiming to manage complications but not prevent disease onset.
  • Long-term prevention in susceptible individuals is crucial for reducing the disease burden.

Purpose of the Study:

  • To explore strategies for the prevention of type 1 diabetes mellitus.
  • To identify methods for early diagnosis of disease predisposition.
  • To investigate potential interventions targeting autoimmunity and beta-cell susceptibility.

Main Methods:

  • Discusses the need for large-scale genetic and serological screening for early diagnosis.
  • Highlights the potential of identifying autoantigen targets for antigen-specific tolerance induction.
  • Examines the use of gene therapy to enhance beta-cell resistance to autoimmune attack.

Main Results:

  • Early diagnosis through genetic and serological screening is essential for prevention.
  • Induction of antigen-specific tolerance offers a pathway for intervention in prediabetes.
  • Gene therapy using resistance-conferring genes presents a potential preventive approach.

Conclusions:

  • Prevention of type 1 diabetes requires early identification of susceptible individuals and targeted interventions.
  • Combining immune system modulation with enhanced beta-cell resilience holds promise for future prevention strategies.
  • Development of safe gene delivery vectors is critical for translating gene therapy approaches into clinical practice.

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...